Study title: Eur J Nucl Med. 1996 May;23(5):504-10. Early and delayed thallium-201 scintigraphy in thyroid nodules: the relationship between early thallium-201 uptake and perfusion. Derebek E, Biberoglu S, Kut O, Yesil S, Saydam S, Yilmaz M, Yenici O, Igci E, GokceEur J Nucl Med. 1996 May;23(5):504-10. Early and delayed thallium-201 scintigraphy in thyroid nodules: the relationship between early thallium-201 uptake and perfusion. Derebek E, Biberoglu S, Kut O, Yesil S, Saydam S, Yilmaz M, Yenici O, Igci E, Gokce
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Diagnosis [E01] | |||||
| Brands: | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: THALLIUM 201T1 CHLORIDE | |||||
| ATC code: V09GX01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |